全文获取类型
收费全文 | 74篇 |
免费 | 28篇 |
专业分类
耳鼻咽喉 | 2篇 |
基础医学 | 2篇 |
临床医学 | 15篇 |
内科学 | 31篇 |
皮肤病学 | 5篇 |
神经病学 | 12篇 |
外科学 | 29篇 |
预防医学 | 3篇 |
眼科学 | 1篇 |
肿瘤学 | 2篇 |
出版年
2023年 | 5篇 |
2022年 | 3篇 |
2021年 | 5篇 |
2020年 | 3篇 |
2019年 | 2篇 |
2018年 | 7篇 |
2017年 | 12篇 |
2016年 | 7篇 |
2015年 | 2篇 |
2014年 | 11篇 |
2013年 | 8篇 |
2012年 | 2篇 |
2011年 | 6篇 |
2010年 | 7篇 |
2009年 | 8篇 |
2008年 | 2篇 |
2007年 | 3篇 |
2006年 | 4篇 |
2003年 | 1篇 |
2000年 | 2篇 |
1999年 | 1篇 |
1998年 | 1篇 |
排序方式: 共有102条查询结果,搜索用时 15 毫秒
1.
Bo Jørgensen MD ; Gitte Juel Friis PhD ; Finn Gottrup MD DMSci 《Wound repair and regeneration》2006,14(3):233-239
Wound pain is a serious problem for elderly patients suffering from chronic leg ulcers, and it may lead to reduced wound healing rates and reduced quality of life. Biatain-Ibu Non-adhesive (Coloplast A/S), a new pain-reducing moist wound healing dressing containing ibuprofen was tested for pain reduction, safety, and efficacy on 10+2 patients in a single-blinded crossover study against Biatain Non-adhesive (Coloplast A/S). Pain was measured with a Numeric Box Scale before, during, and after dressing change. Quality of life was measured using the World Health Organization-5 Well-Being Index. Dressing moist wound healing properties such as absorption capacity and leakage were tested together with assessment of wound exudate and blood plasma content of ibuprofen. Use of the Biatain-Ibu foam dressing correlated with a decrease in pain intensity scores from 7 in the run-in period to approximately 2.5 in the Biatain-Ibu treatment phase. Quality of life measures were improved which together with the reduced pain could contribute to faster wound healing. The moist wound healing properties of Biatain-Ibu were similar to that of the Biatain Non-adhesive and ulcer size was reduced by 24% during the treatment period. Neither side effects nor systemic plasma concentrations of ibuprofen were observed. These data indicate that Biatain-Ibu could reduce persistent and temporary wound pain, increase Quality of life, was found safe to use, and had excellent moist wound healing properties. 相似文献
2.
Construction of meaningful identities in the context of rheumatoid arthritis,motherhood and paid work: A meta‐ethnography 下载免费PDF全文
3.
4.
5.
6.
Fleur E. Brölmann MD Anne M. Eskes MSc PhD Bauer E. Sumpio MD PhD Dieter O. Mayer MD Zena Moore RGN PhD Magnus S. Ågren DMSci Michel Hermans MD Keith Cutting MSc RN Dink A. Legemate MD PhD Hester Vermeulen RN PhD Dirk T. Ubbink MD PhD 《Wound repair and regeneration》2013,21(5):641-647
In wound care research, available high‐level evidence according to the evidence pyramid is rare, and is threatened by a poor study design and reporting. Without comprehensive and transparent reporting, readers will not be able to assess the strengths and limitations of the research performed. Randomized clinical trials (RCTs) are universally acknowledged as the study design of choice for comparing treatment effects. To give high‐level evidence the appreciation it deserves in wound care, we propose a step‐by‐step reporting standard for comprehensive and transparent reporting of RCTs in wound care. Critical reporting issues (e.g., wound care terminology, blinding, predefined outcome measures, and a priori sample size calculation) and wound‐specific barriers (e.g., large diversity of etiologies and comorbidities of patients with wounds) that may prevent uniform implementation of reporting standards in wound care research are addressed in this article. The proposed reporting standards can be used as guidance for authors who write their RCT, as well as for peer reviewers of journals. Endorsement and application of these reporting standards may help achieve a higher standard of evidence and allow meta‐analysis of reported wound care data. The ultimate goal is to help wound care professionals make better decisions for their patients in clinical practice. 相似文献
7.
Rune E. Kuhre PhD Carolyn F. Deacon DMSci Nicolai J. Wewer Albrechtsen PhD Jens J. Holst DMSci 《Diabetes, obesity & metabolism》2021,23(9):2009-2019
Sodium-glucose co-transporter-2 inhibitors (SGLT2is) lower blood glucose and are used for treatment of type 2 diabetes. However, SGLT2is have been associated with increases in endogenous glucose production (EGP) by mechanisms that have been proposed to result from SGLT2i-mediated increases in circulating glucagon concentrations, but the relative importance of this effect is debated, and mechanisms possibly coupling SGLT2is to increased plasma glucagon are unclear. A direct effect on alpha-cell activity has been proposed, but data on alpha-cell SGLT2 expression are inconsistent, and studies investigating the direct effects of SGLT2 inhibition on glucagon secretion are conflicting. By contrast, alpha-cell sodium-glucose co-transporter-1 (SGLT1) expression has been found more consistently and appears to be more prominent, pointing to an underappreciated role for this transporter. Nevertheless, the selectivity of most SGLT2is does not support interference with SGLT1 during therapy. Paracrine effects mediated by secretion of glucagonotropic/static molecules from beta and/or delta cells have also been suggested to be involved in SGLT2i-induced increase in plasma glucagon, but studies are few and arrive at different conclusions. It is also possible that the effect on glucagon is secondary to drug-induced increases in urinary glucose excretion and lowering of blood glucose, as shown in experiments with glucose clamping where SGLT2i-associated increases in plasma glucagon are prevented. However, regardless of the mechanisms involved, the current balance of evidence does not support that SGLT2 plays a crucial role for alpha-cell physiology or that SGLT2i-induced glucagon secretion is important for the associated increased EGP, particularly because the increase in EGP occurs before any rise in plasma glucagon. 相似文献
8.
9.
10.